Regeneron Pharmaceuticals, Inc. Says FDA Extends Priority Review of CAPS Treatment

Nov 1 (Reuters) - Regeneron Pharmaceuticals Inc (REGN.O: Quote, Profile, Research) said U.S. regulators have extended the date for taking action on a priority review of the company's treatment for a rare chronic inflammatory disease known as CAPS.